Mirataz® (mirtazapine transdermal ointment) may help cats gain weight

Mirataz is the first and only FDA-approved transdermal medication for the management of weight loss in cats. As you and your veterinarian team up to determine the underlying cause of your cat’s weight loss, Mirataz may help your cat gain weight.

In clinical studies, Mirataz resulted in significant weight gain in cats experiencing weight loss associated with various conditions.

In clinical studies, Mirataz was well tolerated and used in cats with unintended weight loss associated with a variety of underlying conditions.

What you should know upon discontinuing treatment with Mirataz

Upon discontinuation of Mirataz, it is important to monitor your cat’s food intake. Your cat’s food intake may lessen after discontinuation of Mirataz. If food intake diminishes dramatically (~75%) for several days or if your cat stops eating for more than 48 hours, contact your veterinarian.

Important Safety Information

Mirataz® (mirtazapine transdermal ointment) is for topical use in cats only under veterinary supervision. Do not use in cats with a known hypersensitivity to mirtazapine or any of the excipients or in cats treated with monoamine oxidase inhibitors (MAOIs). Not for human use. Keep out of reach of children. Wear gloves to apply and wash hands after. Avoid contact with treated cat for 2 hours because mirtazapine can be absorbed orally and transdermally.

For product label, including complete safety information, see inside page.

References:

Recognize the signs and learn how you can help

Mirataz® (mirtazapine transdermal ointment)
Your cat’s weight loss could be caused by a variety of issues

A change in your cat’s appetite and unintended weight loss doesn’t always have a simple answer. It could be from non–disease-related stress, like a change in where they eat.² It could be a reaction to psychological stress, like the disappearance of another pet.² Or it could be the beginning of a serious disease, like hyperthyroidism, chronic kidney disease, or inflammatory bowel disease.⁴⁻⁶

Your cat’s weight loss could be detrimental to your cat than the underlying cause.

Monitoring your cat’s health is a team effort

You can help identify the early signs of weight loss at home.

As you interact with your feline friend, observe their eating habits, and take the time to note any changes in their body composition.

Take notice of changes in eating habits including:

- Interest in food
- Amount eaten
- Time to finish

When petting your cat, check for:

- Ribs or bony protrusions
- Lumps or bumps
- Tender spots

If you notice your cat is losing weight, contact your veterinarian immediately.

Important Safety Information

Mirataz® (mirtazapine transdermal ointment) is for topical use in cats only under veterinary supervision. Do not use in cats with a known hypersensitivity to mirtazapine or any of the excipients or in cats treated with monoamine oxidase inhibitors (MAOIs). Not for human use. Keep out of reach of children. Wear gloves to apply and wash hands after. Avoid contact with treated cat for 2 hours following application. The most common adverse reactions include application site reactions, behavioral abnormalities (vocalization and hyperactivity) and vomiting.

For product label, including complete safety information, see inside page.

Mirataz®
(mirtazapine transdermal ointment)
To learn more, visit kindredbio.com/Mirataz.

Talk to your veterinarian about unintended weight loss and how Mirataz can help
Mirataz™ (mirtazapine transdermal ointment) is a white to off-white ointment containing 2% (w/w) of mirtazapine suitable for transdermal (topical) administration. Mirataz™ is indicated for the management of weight loss in cats. Mirataz™ is contraindicated in cats with a known hypersensitivity to mirtazapine or to any of the inactive ingredients. Mirataz™ has not been evaluated in cats ≤2 kg or less than 6 months of age. The use of Mirataz™ has not been evaluated in cats intended for for breeding, pregnant, or nursing cats. Mirataz™ has not been evaluated in cats that are intended for for breeding, pregnant, or nursing cats. Mirataz™ is indicated for the management of weight loss in cats.

Mirtazapine administration resulted in increased vocalization, hyperactivity, attention-seeking, decreased food intake, and gastrointestinal effects such as bloating, diarrhea, vomiting, and diarrhea.

**CONTRAINDICATIONS:**

- Mirataz™ is contraindicated in cats with a known hypersensitivity to mirtazapine or to any of the inactive ingredients.
- Mirataz™ should not be given to cats that are intended for for breeding, pregnant, or nursing cats.

**STORAGE:**

Store below 25°C (77°F). Multi-use tube. Discard within 30 days of first use.

**HOW SUPPLIED:**

- In 1 gram aluminum tube.

**REFERENCES:**


**Animal Safety:**

- The most common adverse reaction was ear pinnae reactions (erythema with or without blood and exudate). The most common adverse reaction was ear pinnae reactions (erythema with or without blood and exudate). The most common adverse reaction was ear pinnae reactions (erythema with or without blood and exudate).

**ADVERSE REACTIONS:**

- In a randomized, double-blinded, vehicle-controlled study to assess the effectiveness and safety of Mirataz™ for the management of weight loss, 115 cats treated with Mirataz™ and 115 cats treated with vehicle control were evaluated on safety. The vehicle control was an ointment containing the same inactive ingredients as Mirataz™ without mirtazapine. The most common adverse reactions in both application site reactions, behavioral abnormalities (vocalization and hyperactivity), and vomiting. The adverse reactions observed in the study and number of cats experiencing each adverse reaction is summarized in Table 1 below.

**PHARMACOLOGY:**

- Antagonists at the peripheral 5-HT2 receptors have been shown to block the orexigenic effects of mirtazapine. The orexigenic effects of mirtazapine are likely mediated through its 5-HT2A receptor antagonism. Inhibition of 5-HT2 receptors may account for the orexigenic effects of mirtazapine. Another hypothesis is that mirtazapine-induced weight gain may occur via a change in response to leptin and the tumor necrosis factor signal.

**PHARMACOKINETICS:**

- When applied topically to the inner pinna of the cat’s ear with ointment, the concentration of mirtazapine in the plasma may be increased by up to 10 times the concentration of mirtazapine in the plasma when applied orally. The mean plasma concentration of mirtazapine was highest at the time of application and decreased rapidly thereafter. The mean plasma concentration of mirtazapine was highest at the time of application and decreased rapidly thereafter. The mean plasma concentration of mirtazapine was highest at the time of application and decreased rapidly thereafter.

**EFFECTIVENESS:**

- In a study to demonstrate the method of administering the dose, the veterinarian or trained personnel at the clinic should apply the first dose in the presence of the owner. To demonstrate the method of administering the dose, the veterinarian or trained personnel at the clinic should apply the first dose in the presence of the owner. To demonstrate the method of administering the dose, the veterinarian or trained personnel at the clinic should apply the first dose in the presence of the owner.

**CONTRAINDICATIONS:**

- Mirataz™ is contraindicated in cats with a known hypersensitivity to mirtazapine or to any of the inactive ingredients. Mirataz™ should not be given to cats that are intended for for breeding, pregnant, or nursing cats. Mirataz™ is indicated for the management of weight loss in cats.

**STORAGE:**

- Store below 25°C (77°F). Multi-use tube. Discard within 30 days of first use.

**HOW SUPPLIED:**

- In 1 gram aluminum tube.

**REFERENCES:**